The estimated Net Worth of Gary M. Phillips is at least $223 Thousand dollars as of 7 September 2023. Gary Phillips owns over 5,437 units of Aldeyra Therapeutics Inc stock worth over $91,686 and over the last 11 years he sold ALDX stock worth over $0. In addition, he makes $131,743 as Independent Director at Aldeyra Therapeutics Inc.
Gary has made over 3 trades of the Aldeyra Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 5,437 units of ALDX stock worth $2,990 on 7 September 2023.
The largest trade he's ever made was buying 9,375 units of Aldeyra Therapeutics Inc stock on 7 May 2014 worth over $75,000. On average, Gary trades about 659 units every 142 days since 2014. As of 7 September 2023 he still owns at least 14,812 units of Aldeyra Therapeutics Inc stock.
You can see the complete history of Gary Phillips stock trades at the bottom of the page.
Dr. Gary M. Phillips M.D. serves as Independent Director of the Company. Dr. Phillips has served as President & CEO of OrphoMed, Inc. since March 2018 and has been a member of our Board of Directors since May 2009. He was Executive Vice President & Chief Strategy Officer at Mallinckrodt Pharmaceuticals plc from October 2013 to March 2018. Before joining our company, Dr. Phillips held the dual roles of president, U.S. surgical and pharmaceuticals and global head of pharmaceuticals at Bausch & Lomb. He has served as the head of global health at the World Economic Forum in Geneva. Previously, he was president of Reckitt Benckiser Pharmaceuticals, Inc. (now Indivior). He has also held executive roles at Merck KGaA, Novartis and Wyeth (now Pfizer). He was a healthcare strategy managing consultant at Towers Perrin (now Willis Towers Watson) and a medical officer with the United States Navy, from which he was honorably discharged as a lieutenant commander. Dr. Phillips was educated at the University of Pennsylvania, where he received an M.D. (Alpha Omega Alpha) from the School of Medicine, an MBA from the Wharton School, and B.A. (summa cum laude, Phi Beta Kappa) in biochemistry from the College of Arts and Sciences. He completed postgraduate medical education at Naval Medical Center San Diego and maintains an active medical license. Dr. Phillips’ extensive knowledge of our business and history, and his experience in pharmaceutical strategy at multiple multinational companies, contributed to our conclusion that he should serve as a director of our company.
As the Independent Director of Aldeyra Therapeutics Inc, the total compensation of Gary Phillips at Aldeyra Therapeutics Inc is $131,743. There are 9 executives at Aldeyra Therapeutics Inc getting paid more, with Todd Brady having the highest compensation of $4,141,260.
Gary Phillips is 54, he's been the Independent Director of Aldeyra Therapeutics Inc since 2009. There are 5 older and 9 younger executives at Aldeyra Therapeutics Inc. The oldest executive at Aldeyra Therapeutics Inc is Jesse Treu, 73, who is the Independent Director.
Gary's mailing address filed with the SEC is C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, LEXINGTON, MA, 02421.
Over the last 10 years, insiders at Aldeyra Therapeutics Inc have traded over $6,285,725 worth of Aldeyra Therapeutics Inc stock and bought 11,547,153 units worth $75,179,936 . The most active insiders traders include Advisors Llcperceptive Life..., & Johnson Johnson & Johnson..., and Advisors Llcedelman Josephp.... On average, Aldeyra Therapeutics Inc executives and independent directors trade stock every 54 days with the average trade being worth of $1,358,662. The most recent stock trade was executed by Stephen Machatha on 12 August 2024, trading 16,041 units of ALDX stock currently worth $76,034.
dedicated to improving lives by developing products that treat aldehyde-mediated diseases. we are a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. we are developing adx-102 (formerly ns2), as well as other novel product candidates that are designed specifically to sequester aldehydes, for the treatment of: • noninfectious anterior uveitis, a rare severe inflammatory eye disease that can lead to blindness; • allergic conjunctivitis, a common disease that affects more than 20% of the population worldwide, and related rare allergic ocular diseases that are characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, swelling, and redness; • dry eye disease, a common inflammatory dise
Aldeyra Therapeutics Inc executives and other stock owners filed with the SEC include: